Loading
ADC Therapeutics SA Stock: price and insider trades · United States
US·Mcap US$185.1M
No insider purchase over the last 90 days. The latest was filed 13 Dec 2024.
ADC Therapeutics SA: what insiders have been doing
ADC Therapeutics SA is a listed company. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 34 filings came from 13 insiders.
Only sales appear on the open market, 6 sales in all totalling €17.0M, filed by 1 insider. Redmile Group, LLC filed the largest sale, €7.5M, on 2 April 2026.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For context, the typical company on the same exchange (median of 5,808 companies) published 19 filings over the same period, against 34 filings here. Over the whole record (from 2024), the tally stands at 2 purchases and 13 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 81.4 m USD and net income at -142.6 m USD.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
78
Thresholds
n/a
Buy Volume
€1M
2 ops. · all time
Sell Volume
€17M
13 ops. · all time
Who traded when
BuySaleRedmile Group, LLC1 buy7 sales
Since the insiders bought
- +110.5%Entry US$2.00 · Close at T+365 US$4.21
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate ADC Therapeutics SA Buy (bullish), based on 3 analysts. Average price target: US$3.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.45
Analyst consensus
3 analystsBuy
US$2.00Target US$3.33(+130%)US$5.00
Income statement
RevenueUS$81.4M
Gross profitUS$75.6M93% margin
EBITDA-US$88.1M-108% margin
Net income-US$142.6M-121.8% margin
Valuation
Beta1.86
Balance sheet & cash
Market capUS$185.1M
Total debtUS$117M
Free Cash Flow-US$141.4M
Profitability & ownership
ROA-19.6%
% insiders14.4%
% institutions67.6%
Last declaration on 2 July 2026
Declarations78 total
675,000 sharesCommon SharesSEC:0001628280-26-047031:0
203,700 sharesCommon SharesSEC:0001628280-26-047033:0
221,100 sharesCommon SharesSEC:0001628280-26-047034:0
213,900 sharesCommon SharesSEC:0001628280-26-047036:0
45,000 shares0Common SharesSEC:0001628280-26-040487:0
45,000 shares0Common SharesSEC:0001628280-26-040488:0
45,000 shares0Common SharesSEC:0001628280-26-040490:0
45,000 shares0Common SharesSEC:0001628280-26-040491:0
45,000 shares0Common SharesSEC:0001628280-26-040492:0
45,000 shares0Common SharesSEC:0001628280-26-040493:0
12,600 shares@ US$3.08100.0% of flowCommon SharesSEC:0001628280-26-040487:1
12,600 shares@ US$3.0836.7% of flowCommon SharesSEC:0001628280-26-040488:1
2,596 shares@ US$3.0836.8% of flowCommon SharesSEC:0001628280-26-040490:1
12,600 shares@ US$3.0836.7% of flowCommon SharesSEC:0001628280-26-040491:1
15,196 shares@ US$3.0838.0% of flowCommon SharesSEC:0001628280-26-040492:1
12,600 shares@ US$3.0836.7% of flowCommon SharesSEC:0001628280-26-040493:1
188,407 shares@ US$3.7523.4% of flowCommon StockSEC:0001104659-26-039359:1
169,265 shares@ US$3.7993.0% of flowCommon StockSEC:0001104659-26-039359:2
162,517 shares@ US$3.7992.9% of flowCommon StockSEC:0001104659-26-039359:3
2,634,506 shares@ US$3.27941.1% of flowCommon StockSEC:0001104659-26-039359:4
196,229 shares@ US$3.7523.5% of flowCommon StockSEC:0001104659-26-039359:0
2,529,491 shares@ US$3.27939.5% of flowCommon StockSEC:0001104659-26-039359:5
62,900 shares@ US$3.9967.0% of flowCommon SharesSEC:0001628280-26-009283:0
25 of 78 declarations
About ADC Therapeutics SA
ADC Therapeutics SA is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. It specializes in antibody-drug conjugates and innovative treatments to improve patient outcomes.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
